High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1

Cell Cycle

Volumn 10, Issue 22, 2011, Pages 3948-3956

  Yellen, Paige ^a   Saqcena, Mahesh ^a   Salloum, Darin ^a   Feng, Jiangnan ^a   Preda, Angela ^a   Xu, Limei ^a   Rodrik Outmezguine, Vanessa ^b   Foster, David A ^a  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

4E BP1; Akt; Apoptosis; eIF4E; mTOR; Rapamycin

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; PROTEIN PHOSPHORYLATION;

EUKARYOTA; MAMMALIA; RAPTORES;

EID: 81855224569     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.22.18124     Document Type: Article

References (53)

1. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID:21157483; DOI:10.1038/nrm3025.
2. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22; PMID:17613433; DOI:10.1016/j.ccr.2007.05.008.
3. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003; 4:343-8; PMID:14667501; DOI:10.1016/S1535-6108(03)00275-7.
4. Zhang YJ, Duan Y, Zheng XF. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 2011; 16:325-31; PMID:21333749; DOI:10.1016/j.drudis.2011.02.008.
5. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009; 8:1026-9; PMID:19270529; DOI:10.4161/cc.8.7.8044.
6. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009; 29:1411-20; PMID:19114562; DOI:10.1128/MCB.00782-08.
7. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003; 22:3937-42; PMID:12813467; DOI:10.1038/sj.onc.1206565.
8. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159-68; PMID:16603397; DOI:10.1016/j.molcel.2006.03.029.
9. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296-302; PMID:15268862; DOI:10.1016/j.cub.2004.06.054.
10. Choo AY, Blenis J. Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle 2009; 8:567-72; PMID:19197153; DOI:10.4161/cc.8.4.7659.
11. Gadir N, Jackson DN, Lee E, Foster DA. Defective TGFbeta signaling sensitizes human cancer cells to rapamycin. Oncogene 2008; 27:1055-62; PMID:17700525; DOI:10.1038/sj.onc.1210721.
12. Chen Y, Rodrik V, Foster DA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene 2005; 24:672-9; PMID:15580312; DOI:10.1038/sj.onc.1208099.
13. Easton JB, Houghton PJ. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 2004; 8:551-64; PMID:15584862; DOI:10.1517/14728222.8.6.551.
14. Oh WJ. Jacinto E. mTOR complex 2 signaling and functions. Cell Cycle 2011; 10:2305-16; PMID:21670596; DOI:10.4161/cc.10.14.16586.
15. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284:8023-32; PMID:19150980; DOI:10.1074/jbc.M900301200.
16. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 2008; 105:17414-9; PMID:18955708; DOI:10.1073/pnas.0809136105.
17. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, Petroulakis E, et al. mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 2010; 328:1172-6; PMID:20508131; DOI:10.1126/science. 1187532.
18. Albers MW, Brown EJ, Tanaka A, Williams RT, Hall FL, Schreiber SL. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line. J Biol Chem 1993; 268:22825-9; PMID:8226793.
19. +/-mice. Proc Natl Acad Sci USA 2001; 98:10320-5; PMID:11504907; DOI:10.1073/pnas.171060098.
20. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98:10314-9; PMID:11504908; DOI:10.1073/pnas.171076798.
21. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J. mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004; 24:200-16; PMID:14673156; DOI:10.1128/MCB.24.1.200-16.2004.
22. Jackman J, O'Connor PM. Methods for synchronizing cells at specific stages of the cell cycle. Curr Protoc Cell Biol 2001; 8:3.
23. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15:2852-64; PMID:11691836.
24. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163-75; PMID:12150925; DOI:10.1016/S0092-8674(02)00808-5.
25. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8; PMID:16103051; DOI:10.1158/0008-5472.CAN-05-0917.
26. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8; PMID:16452206; DOI:10.1158/0008-5472.CAN-05- 2925.
27. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68:7409-18; PMID:18794129; DOI:10.1158/0008-5472.CAN-08-1522.
28. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261-74; PMID:17604717; DOI:10.1016/j.cell.2007.06.009.
29. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR Mediated Anticancer Drug Discovery. Drug Discov Today Ther Strateg 2009; 6:47-55; PMID:20622997; DOI:10.1016/j.ddstr.2009.12.001.
30. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70:288-98; PMID:20028854; DOI:10.1158/0008-5472.CAN-09-1751.
31. Bjornsti MA, Houghton PJ. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 2004; 5:519-23; PMID:15193254; DOI:10.1016/j.ccr.2004.05.027.
32. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433:477-80; PMID:15690031; DOI:10.1038/ nature03205.
33. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428:332-7; PMID:15029198; DOI:10.1038/nature02369.
34. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990; 345:544-7; PMID:2348862; DOI:10.1038/345544a0.
35. Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 2009; 16:439-46; PMID:19878875; DOI:10.1016/j.ccr.2009. 09.025.
36. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10:484-6; PMID:15098029; DOI:10.1038/nm1042.
37. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17:249-61; PMID:20227039; DOI:10.1016/j.ccr.2010.01.021.
38. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18:39-51; PMID:20609351; DOI:10.1016/j.ccr.2010.05.023.
39. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, et al. Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 2009; 15:2872-8; PMID:19336517; DOI:10.1158/1078-0432.CCR-08-2336.
40. Houghton PJ. Everolimus. Clin Cancer Res 2010; 16:1368-72; PMID:20179227; DOI:10.1158/1078-0432.CCR-09-1314.
41. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5:8; PMID:18215105; DOI:10.1371/journal.pmed.0050008.
42. Jimeno A, Rudek MA, Kulesza P, Ma WW, Wheelhouse J, Howard A, et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 2008; 26:4172-9; PMID:18757332; DOI:10.1200/JCO.2008.16.2347.
43. Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell 2010; 38:768-74; PMID:20542007; DOI:10.1016/j.molcel.2010.05.017.
44. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmaco-dynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26:1603-10; PMID:18332469; DOI:10.1200/JCO.2007.14.5482.
45. Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010; 107:12469-74; PMID:20616057; DOI:10.1073/pnas.1005114107.
46. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7:11-20; PMID:18177721; DOI:10.1016/j. cmet.2007.10.002.
47. Chen X, Hui L, Foster DA, Drain CM. Efficient synthesis and photodynamic activity of porphyrinsaccharide conjugates: Targeting and incapacitating cancer cells. Biochemistry 2004; 43:10918-29; PMID:15323552; DOI:10.1021/bi049272v.
48. Blagosklonny MV. Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal. Cell Cycle 2010; 9:4788-94; PMID:21150328; DOI:10.4161/cc.9.24.14360.
49. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging 2009; 1:281-8; PMID:20157517.
50. Foster DA. Reduced mortality and moderate alcohol consumption: The phospholipase D-mTOR connection. Cell Cycle 2010; 9:1291-4; PMID:20372065; DOI:10.4161/cc.9.7.11145.
51. Stephan S, Datta K, Wang E, Li J, Brekken RA, Parangi S, et al. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer. Clin Cancer Res 2004; 10:6993-7000; PMID:15501979; DOI:10.1158/1078-0432.CCR-04-0808.
52. Abrams SL, Steelman LS, Shelton JG, Chappell W, Bäsecke J, Stivala F, et al. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle 2010; 9:1839-46; PMID:20436269; DOI:10.4161/cc.9.9.11544.
53. Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009; 8:18-22; PMID:19106609; DOI:10.4161/cc.8.1.7324.